Latest News and Press Releases

Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months ...

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday,...

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood...

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing...

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday,...

LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled...

LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical...

Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney...

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in...